These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 23361871

  • 1. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ, Vis JC, van Dijk AP, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RH, Mulder BJ, Bouma BJ.
    Eur J Heart Fail; 2013 Jun; 15(6):690-8. PubMed ID: 23361871
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of endothelin blockade in adults with Fontan physiology.
    Derk G, Houser L, Miner P, Williams R, Moriarty J, Finn P, Alejos J, Aboulhosn J.
    Congenit Heart Dis; 2015 Jun; 10(1):E11-6. PubMed ID: 24890846
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of a trial on the role of bosentan in Fontan patients: improvement of exercise capacity?
    Schuuring MJ, Vis JC, Bouma BJ, van Dijk AP, van Melle JP, Pieper PG, Vliegen HW, Sieswerda GT, Mulder BJ.
    Contemp Clin Trials; 2011 Jul; 32(4):586-91. PubMed ID: 21527360
    [Abstract] [Full Text] [Related]

  • 4. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study.
    Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L.
    Circulation; 2014 Dec 02; 130(23):2021-30. PubMed ID: 25446057
    [Abstract] [Full Text] [Related]

  • 5. The effect of bosentan in patients with a failing Fontan circulation.
    Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L.
    Cardiol Young; 2009 Aug 02; 19(4):331-9. PubMed ID: 19519964
    [Abstract] [Full Text] [Related]

  • 6. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG, Vis JC, van Loon RL, Nieuwkerk PT, van Dijk AP, Hoendermis ES, de Bruin-Bon RH, Bouma BJ, Bresser P, Berger RM, Mulder BJ.
    Am J Cardiol; 2009 May 01; 103(9):1309-15. PubMed ID: 19406277
    [Abstract] [Full Text] [Related]

  • 7. The safety and effects of bosentan in patients with a Fontan circulation.
    Bowater SE, Weaver RA, Thorne SA, Clift PF.
    Congenit Heart Dis; 2012 May 01; 7(3):243-9. PubMed ID: 22348734
    [Abstract] [Full Text] [Related]

  • 8. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of treatment with bosentan in patients with carcinoid heart disease: single center study.
    Lafaras CT, Mandala EM, Platogiannis DN, Saratzis AN, Barbetakis NG, Paraskevopoulos PP, Ilonidis GC, Bischiniotis TS.
    Onkologie; 2010 May 04; 33(6):300-4. PubMed ID: 20523093
    [Abstract] [Full Text] [Related]

  • 10. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C, Praino E, Nivuori M, di Serio F, Lapadula G, Iannone F.
    Int J Rheum Dis; 2017 Jan 04; 20(1):90-96. PubMed ID: 26218502
    [Abstract] [Full Text] [Related]

  • 11. Value of N-terminal pro brain natriuretic peptide levels in different types of Fontan circulation.
    Heck PB, Müller J, Weber R, Hager A.
    Eur J Heart Fail; 2013 Jun 04; 15(6):644-9. PubMed ID: 23610138
    [Abstract] [Full Text] [Related]

  • 12. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, Miyawaki T.
    J Thorac Cardiovasc Surg; 2010 Aug 04; 140(2):346-51. PubMed ID: 20434177
    [Abstract] [Full Text] [Related]

  • 13. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G.
    Am J Respir Crit Care Med; 2008 Jan 01; 177(1):75-81. PubMed ID: 17901413
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP, Dimopoulos K, Kaya MG, Harries C, Uebing A, Li W, Koltsida E, Gibbs JS, Gatzoulis MA.
    Heart; 2007 Aug 01; 93(8):974-6. PubMed ID: 17639112
    [Abstract] [Full Text] [Related]

  • 15. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep 01; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial.
    Shang XK, Lu R, Zhang X, Zhang CD, Xiao SN, Liu M, Wang B, Dong NG.
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug 01; 36(4):534-540. PubMed ID: 27465329
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome 5 to 18 years after the Fontan operation performed on children younger than 5 years.
    Robbers-Visser D, Kapusta L, van Osch-Gevers L, Strengers JL, Boersma E, de Rijke YB, Boomsma F, Bogers AJ, Helbing WA.
    J Thorac Cardiovasc Surg; 2009 Jul 01; 138(1):89-95. PubMed ID: 19577062
    [Abstract] [Full Text] [Related]

  • 18. Relation of systemic venous return, pulmonary vascular resistance, and diastolic dysfunction to exercise capacity in patients with single ventricle receiving fontan palliation.
    Goldstein BH, Connor CE, Gooding L, Rocchini AP.
    Am J Cardiol; 2010 Apr 15; 105(8):1169-75. PubMed ID: 20381672
    [Abstract] [Full Text] [Related]

  • 19. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.
    Regul Pept; 2008 Nov 29; 151(1-3):48-53. PubMed ID: 18796317
    [Abstract] [Full Text] [Related]

  • 20. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct 29; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.